Replimune Group Inc.
REPL
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$271M
▼ -26.9% YoY
Op. Margin
–
ROIC
-76.50%
▼ -21.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$246M
▼ -43.0% YoY
Op. Cash Flow (TTM)
-$246M
▼ -45.8% YoY
Net Debt
-$181M
Net Cash Position
Cash & Equiv.
$308M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL
Held by ETFs
REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:
Replimune Group (REPL) in two numbers
Questions about Replimune Group
Does Replimune Group (REPL) pay a dividend?
No. Replimune Group (REPL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 23 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in REPL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing REPL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.